Phase III studies of primary and booster doses of investigational meningococcal serogroup B vaccine (4CMenB)

Source: Lancet Area: News According to Phase III data published early online in the Lancet, an investigational meningococcal serogroup B vaccine (4CMenB) led to an immune response against four reference serogroup B meningococcal strains in 84-100% of infants, and in 95-100% after a 12-month booster dose, without any clinically significant effect on routine childhood vaccines.   The authors note that meningococcal serogroup B is now the most prominent cause of infant bacterial meningitis and septicaemia in Europe. As serogroup B polysaccharide is immunologically similar to that of human neural-cell adhesion molecules, the traditional polysaccharide conjugate-vaccine approach has not been possible. Genome mining identified three possible antigens that could be used in vaccine development (factor H binding protein, neisserial adhesin A, and neisseria heparin binding antigen) and in preliminary studies, formulations of these antigens were found to induce antibodies in infants that killed several ...
Source: NeLM - News - Category: Drugs & Pharmacology Source Type: news